Another pre-clinical example is that menin inhibitor SNDX-5613 combined with BCL2 inhibitor venetoclax shows synergistic activity in patient-derived KMT2Ar AML cells and PDX mouse models (Fiskus et al., 2022). This evidence concerns the gene MEN1 and acute myeloid leukemia.